The Effects of Atorvastatin on the Prevention of Osteoporosis and Dyslipidemia in the High-Fat-Fed Ovariectomized Rats

Calcified Tissue International

Volumn 96, Issue 6, 2015, Pages 541-551

  Lin, Sien ^a,b,c   Huang, Jianping ^a   Fu, Ziwei ^a   Liang, Yanlong ^a   Wu, Haiyou ^a   Xu, Liangliang ^b   Sun, Yuxin ^b   Lee, Wayne Y W ^b,c   Wu, Tie ^a   Qin, Ling ^b   Cui, Liao ^a   Li, Gang ^b,c  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Atorvastatin; Dyslipidemia; Osteoporosis; Ovariectomy; Rat

Indexed keywords

ATORVASTATIN; CALCEIN; CALCIUM; CHOLESTEROL; COLLAGEN; HIGH DENSITY LIPOPROTEIN; HYDROXYPROLINE; LOW DENSITY LIPOPROTEIN; PHOSPHORUS; TRIACYLGLYCEROL; WATER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOMECHANICS; BODY WEIGHT; BONE DEMINERALIZATION; CHEMICAL COMPOSITION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORTICAL BONE; DRUG EFFECT; DYSLIPIDEMIA; ENERGY ABSORPTION; FATTY LIVER; FEMALE; HISTOLOGY; LIPID DIET; LIPID STORAGE; LIVER WEIGHT; MECHANICAL STIMULUS TEST; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOPOROSIS; OVARIECTOMY; PRIORITY JOURNAL; RAT; TRABECULAR BONE; TRIACYLGLYCEROL BLOOD LEVEL; UTERUS WEIGHT; WEIGHT CHANGE; ANIMAL; ANIMAL FOOD; BONE DENSITY; DISEASE MODEL; DRUG EFFECTS; DYSLIPIDEMIAS; HUMAN; OSTEOPOROSIS, POSTMENOPAUSAL; SPRAGUE DAWLEY RAT;

ANIMAL FEED; ANIMALS; ATORVASTATIN CALCIUM; BONE DENSITY; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; OSTEOPOROSIS, POSTMENOPAUSAL; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY; X-RAY MICROTOMOGRAPHY;

EID: 84929705475     PISSN: 0171967X     EISSN: 14320827     Source Type: Journal    
DOI: 10.1007/s00223-015-9975-7     Document Type: Article

References (40)

1. Xia WB, He SL, Xu L, Liu AM, Jiang Y, Li M, Wang O, Xing XP, Sun Y, Cummings SR (2012) Rapidly increasing rates of hip fracture in Beijing, China. J Bone Miner Res 27:125–129
2. Cooper C, Cole ZA, Holroyd CR, Earl SC, Harvey NC, Dennison DM, Melton LJ, Cummings SR, Kanis JA (2011) Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int 22:1277–1288
3. Wohl GR, Loehrke L, Watkins BA, Zernicke RF (1998) Effects of high-fat diet on mature bone mineral content, structure, and mechanical properties. Calcif Tissue Int 63:74–79
4. van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S (1999) Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 264:108–111
5. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA, Reszka AA (1999) Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 96:133–138
6. Halcox JP, Deanfield JE (2004) Beyond the laboratory: clinical implications for statin pleiotropy. Circulation 109:II42–II48
7. Maritz FJ, Conradie MM, Hulley PA, Gopal R, Hough S (2001) Effect of statins on bone mineral density and bone histomorphometry in rodents. Arterioscler Thromb Vasc Biol 21:1636–1641
8. Drake Matthew T, Clarke Bart L, Khosla Sundeep (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83:1032–1045
9. Grasser WA, Baumann AP, Petras SF, Harwood HJ Jr, Devalaraja R, Renkiewicz R, Baragi V, Thompson DD, Paraklar VM (2003) Regulation of osteoclast differentiation by statins. J Musculoskelet Neuronal Interact 3:53–62
10. Chen PY, Sun JS, Tsuang YH, Chen MH, Weng PW, Lin FH (2010) Simvastatin promotes osteoblast viability and differentiation via Ras/Smad/Erk/BMP-2 signaling pathway. Nutr Resm 30:191–199
11. Maeda T, Matsunuma A, Kawane T, Horiuchi N (2001) Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem Biophys Res Commun 280:874–877
12. Chan KA, Andrade SE, Boles M, Buist DS, Chase GA, Donahue JG, Goodman MJ, Gurwitz JH, LaCroix AZ, Platt R (2000) Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 355:2185–2188
13. Uysal AR, Delibasi T, Erdogan MF, Kamel N, Baskal N, Tonyukuk V, Corapcioglu D, Güllü S, Erdogan G (2007) Effect of simvastatin use on bone mineral density in women with type 2 diabetes. Endocr Pract 13:114–116
14. Majima T, Komatsu Y, Fukao A, Ninomiya K, Matsumura T, Nakao K (2007) Short term effects of atorvastatin on bone turnover in male patients with hypercholesterolemia. Endocr J 54:145–151
15. Majima T, Shimatsu A, Komatsu Y, Satoh N, Fukao A, Ninomiya K, Matsumura T, Nakao K (2007) Shortterm effects of pitavastatin on biochemical markers of bone turnover in patients with hypercholesterolemia. Intern Med 46:1967–1973
16. Safaei H, Janghorbani M, Aminorroaya A, Amini M (2007) Lovastatin effects on bone mineral density in postmenopausal women with type 2 diabetes mellitus. Acta Diabetol 44:76–82
17. Schoofs MW, Sturkenboom MC, van der Klift M, Hofman A, Pols HA, Stricker BH (2004) HMG-CoA reductase inhibitors and the risk of vertebral fracture. J Bone Miner Res 19:1525–1530
18. Rejnmark L, Olsen ML, Johnsen SP, Vestergaard P, Sorensen HT, Mosekildeb L (2004) Hip fracture risk in statin users: a population-based Danish case-control study. Osteoporos Int 15:452–458
19. Hatzigeorgiou C, Jackson JL (2005) Hydroxymethylglutaryl-coenzyme A reductase inhibitors and osteoporosis: a meta-analysis. Osteoporos Int 16:990–998
20. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY (2007) Effects of statins on bone mineral density: a meta-analysis of clinical studies. Bone 40:1581–1587
21. Bone HG, Kiel DP, Lindsay RS, Lewiecki EM, Bolognese MA, Leary ET, Lowe W, McClung MR (2007) Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial. J Clin Endocrinol Metab 92:4671–4677
22. Huang JH, Huang XH, Chen ZY, Zheng QS, Sun RY (2004) Dose conversion among different animals and healthy volunteers in pharmacological study. Chin J Clin Pharmacol Ther 9:1069–1072
23. U.S. Food and Drug Administration (2005) FDA Guidance for industry and reviews estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Available from: http://www.fda.gov/downloads/Drugs/Guidances/UCM078932.pdf Accessed 07 May 2005
24. Lin SE, Huang JP, Wu LZ, Wu T, Cui L (2013) Prevention of osteopenia and dyslipidemia in rats after ovariectomy with combined aspirin and low-dose diethylstilbestrol. Biomed Environ Sci 26:249–257
25. Cui L, Li T, Liu Y, Li P, Xu B, Huang L, Chen Y, Liu Y, Tian X, Jee WS, Wu T (2012) Salvianolic acid B prevents bone loss in prednisone-treated rats through stimulation of osteogenesis and bone marrow angiogenesis. PLoS One 7:e34647
26. Lin SE, Huang JP, Zheng L, Liu YZ, Liu GH, Li N, Wang KX, Zou LY, Wu T, Qin L, Cui L, Li G (2014) Glucocorticoid-induced osteoporosis in growing rats. Calcif Tissue Int 95:362–373
27. Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR, Parfitt AM (2013) Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 28:2–17
28. Campbell GM, Bernhardt R, Scharnweber D, Boyd SK (2011) The bone architecture is enhanced with combined PTH and alendronate treatment compared to monotherapy while maintaining the state of surface mineralization in the OVX rat. Bone 49:225–232
29. Mahanti HS, Barnes RM (1983) Determination of major, minor and trace elements in bone by inductively-coupled plasma emission spectrometry. Anal Chim Acta 151:409–417
30. Little Tanya J, Feinle-Bisset Christine (2010) Oral and gastrointestinal sensing of dietary fat and appetite regulation in humans: modification by diet and obesity. Front Neurosci 4:178
31. Paquette A, Shinoda M, Rabasa Lhoret R, Prud’homme D, Lavoie JM (2007) Time course of liver lipid infiltration in ovariectomized rats: impact of a high-fat diet. Maturitas 58:182–190
32. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110:227–239
33. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–2497
34. Stein EA (2003) The power of statins: aggressive lipid lowering. Clin Cardiol 26:III25–III31
35. Parhami F, Tintut Y, Beamer WG, Gharavi N, Goodman W, Demer LL (2001) Atherogenic high-fat diet reduces bone mineralization in mice. J Bone Miner Res 16:182–188
36. Cao JJ, Gregoire BR, Gao H (2009) High-fat diet decreases cancellous bone mass but has no effect on cortical bone mass in the tibia in mice. Bone 44:1097–1104
37. Patsch JM, Kiefer FW, Varga P, Pail P, Rauner M, Stupphann D, Resch H, Moser D, Zysset PK, Stulnig TM, Pietschmann P (2011) Increased bone resorption and impaired bone microarchitecture in short-term and extended high-fat diet-induced obesity. Metabolism 60:243–249
38. Seeman E, Delmas PD (2006) Bone quality–the material and structural basis of bone strength and fragility. N Engl J Med 354:2250–2261
39. Kaji H, Kanatani M, Sugimoto T, Chihara K (2005) Statins modulate the levels of osteoprotegerin/receptor activator of NFκB ligand mRNA in mouse bonecell cultures. Horm Metab Res 37:589–592
40. Viereck V, Grundker C, Blaschke S, Frosch KH, Schoppet M, Emons G, Hofbauer LC (2005) Atorvastatin stimulates the production of osteoprotegerin by human osteoblasts. J Cell Biochem 96:1244–1253